Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

SAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor ...

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...

It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat. J&J holds a leadership role in diverse healthcare ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Several high-profile health systems will take the stage at JPM across Monday and Tuesday. Highlights include presentations from Ascension, AdventHealth, Intermountain Healthcare and Providence on ...